Researchers developed a cohort study of more than 14,000 participants to determine whether there is an association between statin initiation and a reduced risk of mortality and major adverse cardiovascular...
The development of new treatment options for nephropathic cystinosis has resulted in a higher likelihood of survival to adulthood for these patients but has also introduced new challenges in management....
In the ILLUMINATE-C trial, patients with advanced primary hyperoxaluria type 1 and severe renal impairment treated with lumasiran showed decreased plasma oxalate and good safety profiles at 6 months and 12...
Oxalate nephropathy is a commonly underrecognized cause of chronic kidney disease and end-stage kidney disease with multiple etiologies, including primary hyperoxaluria, enteric hyperoxaluria, or ingestion...
Researchers examined a new manifestation of primary hyperoxaluria that has rarely been described in previous literature and reviewed best approaches to managing dental complications in this patient...
Primary hyperoxaluria type 1 is a rare disease that is frequently diagnosed late due to its similar clinical presentation to other types of kidney disease. To better understand the characteristics of...
Individuals with primary hyperoxaluria type 1 are at an increased risk of urinary stone disease, nephrocalcinosis, and chronic kidney disease due to increased hepatic oxalate production. Researchers...
The once-monthly RNA interference injection medication received FDA approval based on results from the phase II PHYOX2 clinical trial and phase III PHYOX3 extension study.
In a randomized clinical trial, a team of researchers compared the use of cefepime and piperacillin-tazobactam—commonly used medications for empirical treatment of infection—to determine the risks of...
